Coronavirus / COVID

Vaccine manufacturer Valneva recently announced it was initiating a phase 1/2 trial in the United Kingdom.

Anti-COVID-19 nanobodies may potentially be effective at preventing and diagnosing infections.

Phase 3 trial data shows experimental monoclonal antibody not to be efficacious.

While ACE2 expression has been reported in the human brain, the cell-specific expression pattern of ACE2 is unknown.

The agreement could mean upwards of 70 million more doses for eligible patients in mid-2021.

Characterizing SARS-CoV-2 interactions can improve understanding of viral RNA functions and the host innate immune response.

Regional and national decision-making can be informed by the online model, called the COVID-19 Pool Tool.

Though research is pending, the CEO used simple science to explain why the mRNA vaccine may still prevent from the UK variant.

The study helps to illuminate how spike proteins initiate infections.

Countries across Europe are reinstating travel bans and lockdowns to combat virus.

A new case series report highlights the unique circumstances of infant illness associated with COVID-19.

New data suggests informed, practical pooled testing could improve both public health response and clinical assessment of the pandemic.

Healthcare providers may want to consider these risks when determining which COVID-19 patients could benefit the most from the new monoclonal antibody therapies.

The VRBPAC voted 20-0 with 1 abstention to support the benefit-risk profile associated with mRNA-1273.

The authors note that the difference in hospitalization rate may be partly due to existing immunity to influenza in the population.

Regimen reduces mortality and recovery time in patients severely ill with pneumonia caused by the virus.

At the interim analysis, the mRNA-1273 vaccine was found to have an efficacy of 94.5% against confirmed COVID-19.

Review of data in trial registries shows they specifically excluded this group from studies involving therapies.

Up to 40% more doses—or, enough to vaccinate another person with two doses—has been observed in the vials distributed at the beginning of this week.

Covaxx CEO Mei Mei Hu has seen vaccines from development all the way through to government approval. She offers her unique perspective into vaccine creation and an update on her company’s COVID-19 vaccine.

New research finds the rate of psychological distress among US adults remained more than 3 times higher than normal in the early months of the pandemic.

Host genetic variants associated with critical illness may identify mechanistic targets for therapeutic development.

UV light-emitting diodes are an emerging technology and a UV source for pathogen inactivation.

This non-prescription test allows users to perform and get results themselves without a medical provider or laboratory needed.